PI Industries Ltd. has released its presentation for the Q2 FY27 earnings conference call, covering the unaudited financial results for the quarter and half-year ended September 30, 2026. The presentation details the company’s financial performance, including revenue, EBITDA, and PAT, highlighting growth in domestic brands and biologicals, while noting impacts on exports. It also outlines key updates on business strategy, ESG initiatives, and future outlook.
PI Industries Ltd. Presents Q2 FY27 Financial Highlights
PI Industries Ltd. has formally communicated its presentation for the Earnings Conference Call, focusing on the unaudited financial results for the quarter and half-year ended September 30, 2026. This disclosure follows the company’s letter dated October 27, 2026, regarding the scheduled call for Analysts and Investors.
Key Financial Performance Metrics
The financial results for Q2 FY27 (Consolidated) indicate revenue of INR 17,018 Mn, a 9% decrease, with EBITDA at INR 2,362 Mn (57% decrease) and PAT at INR 1,222 Mn (70% decrease). For the HTFY27 (Consolidated), revenue stood at INR 34,041 Mn (10% decrease), EBITDA at INR 6,055 Mn (43% decrease), and PAT at INR 3,664 Mn (55% decrease).
The company highlighted that Q2 Agchem Exports declined by 18% due to lower demand, genericization, and pricing pressure. Conversely, Q2 Domestic revenue grew by 19%. Within the Biologicals segment, Global growth was +250% and Domestic growth was +45%. Q2 Health Sciences revenue grew by 20%, and trade working capital was reduced by 18 days.
Operational and Strategic Updates
For Q2FY27, the presentation noted that Agchem exports declined by approximately 18%, attributed to volume growth post-genericization and cost escalation not fully passed on. Domestic revenue saw a growth of around 19%, with Biologicals growing aggressively by 45%+. Health Sciences revenue increased by 20%, including the commencement of commercial GMP manufacturing of Galidesivir (API). Global biologicals experienced a significant growth of +250%, driven by expansion in US, Brazil, and Mexico.
Gross Margin was impacted by a 5% increase in input costs and pricing pressure. Overheads increased due to continued investments in new businesses (6%) and R&D (2%), alongside new molecule launch expenses (1%) and energy costs (3%).
H1 FY27 Performance
In H1 FY27, Agchem exports declined by approximately 15% due to soft demand and pricing pressure. Domestic revenue grew by about 12% despite pricing pressure. Biologicals saw aggressive growth of 55%+ with two products launched. Health Sciences revenue decreased by 4%. Global Biologicals grew by +96%. Gross Margin was impacted by higher input costs (3%) and pricing pressure.
Balance Sheet Strength
The Balance Sheet as of September 26 shows Shareholders Fund at INR 1,14,574 Mn. Net Working Capital was reduced by 18 days (from 139 days in March 26 to 121 days in Sep-26), releasing INR 2,981 Mn cash. Surplus cash net of Debt stands at INR 35,737 Mn. Total capex for H1FY27 was INR 5,674 Mn.
Strategic Vision and Business Segments
PI Industries is transforming into a Life Sciences company, driven by innovation and partnership, evolving from AgSciences. The company emphasizes its journey from a ‘Leading Agri Distribution player’ in 1961 to a ‘Top 5 Global CSM player’ by 1995, and now moving towards ‘Innovation led Agsciences’ and ‘Agsciencess -> Lifesciences’.
Key business segments include:
- Biologicals: A global technology play focusing on Biostimulants, Biocontrol, and plant-nutrition solutions. Q2 FY27 revenue saw growth of 250%+.
- NCEs in Agchem: Global Innovator focusing on novel, patented crop-protection molecules.
- Specialty & Electronic Chemicals: Niche process technology for high-purity chemicals.
- Pharma CRDMO: A differentiated business model for Contract research, development, and manufacturing for pharma.
R&D and Innovation
The company boasts a state-of-the-art R&D platform with labs at 4 locations, employing 700+ scientists, including 200+ Doctorates, and holding 265+ patents. PI Industries is the 1st Indian company to innovate “PIOXANILIPROLE”. The pipeline roadmap includes Pioxaniliprole’s launch in India, followed by global launch, and a next wave of 2-3 molecules in advanced stages.
Global Presence and Partnerships
PI Industries maintains a global presence with 8 Mfg. Sites, 10+ Overseas Offices, and a workforce of 4,000+ Employees. The company emphasizes strong global relationships and a non-conflicting business model across the Ag-chem value chain, partnering with global innovators.
Sustainability and Community Commitment
The company is embedding sustainability into its long-term value creation, with key highlights in environmental, social, and governance aspects. PI Industries has been featured in the S&P Global Sustainability Yearbook for the 3rd consecutive year and ranks among the Top 25 companies globally in the chemical sector.
Commitment to the community is demonstrated through initiatives in Health & Hygiene, Women Empowerment, Education & Skill Development, and Environmental Sustainability.
Source: BSE
